We are not surprised, just disappointed. Reuters reports that next year, pharmaceutical giant Pfizer plans to nearly quadruple the price based on the dose of its COVID-19 vaccine, raising prices from $20 to $30 based on the shot to $110 to $130.
Particularly striking: Experts, according to Reuters, estimate that at this price, the vaccine costs 10,000 times what it costs Pfizer to manufacture.
People’s Vaccine Alliance, a foreign organization committed to protecting vaccines, reportedly condemned the price hike as a “daylight robbery. “Of course, for Pfizer, raising prices would be a very lucrative decision. Like other U. S. pharmaceutical companies, As a U. S. company, Pfizer is first and foremost a company. As demand for COVID vaccines, once overwhelming, continues to decline, it’s a way for Pfizer to maintain profits from previous vaccines, and then some: Wells Fargo analyst Mohit Bansal told Reuters the proposal will most likely yield between $2. 5 billion and $3 billion.
But bad news for those who, you know, want to get vaccinated, want others vaccinated, or want vaccines to be affordable. And unfortunately for the latter group, experts unfortunately expect other vaccine providers to fit their needs.
“We expect Moderna to adapt to this signal,” SVB Securities analyst David Risinger said in a study note, according to Reuters. He reportedly added that he expects Pfizer/BioNTech, Moderna and Novavax to all be “[priced] at a diversity for the foreseeable future. “
Moderna declined Reuters’ request for comment, but in the past advised setting its ad with a value of between $64 and $100 depending on the shot.
It should be noted that, compared to the average annual cost of flu vaccines, the costs of vaccines submitted through Pfizer are far from normal. According to Reuters, the U. S. government up to $70 for higher doses. And on that note, it’s infuriating to wonder where the billions of passengers who will most likely soon be bagged through Pfizer might go.
Are Pfizer costs sociopathic?Annoying?Impressive?Of course. But for better or, in this case, almost for worse, it’s U. S. fitness care. It looks like vaccine brands could run out of pandemic goodwill.
Read more about the eyes of Pfizer’s dollar signal: Pharmaceutical executives plan to do more with COVID vaccine